bristol-myers squibb

Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company...

The earnings crunch is in full swing this this week. Quarterly results are due from the likes of Caterpillar (NYSE: CAT), Exxon Mobil (NYSE: XOM), Procter & Gamble (NYSE: PG) and United Parcel Service (NYSE: UPS), from which analysts expect to see year-over-year earnings growth, as well as...

Health care companies Bristol-Myers Squibb (NYSE: BMY) and Quidel (NASDAQ: QDEL) reached new 52-week highs of $32.75 and $17.21 per share, respectively, in Wednesday's trading session. Bristol-Myers saw its price target boosted by a Bank of America/Merrill Lynch analyst yesterday on belief that...

In a report focusing on Bristol-Myers Squibb (NYSE: BMY), Jefferies said that it anticipates the next “key event in the oral anticoagulant space to be the US approval of Xarelto for post-orthopaedic VTE prevention (PDUFA date 4th July), as it would effectively de-risk the approval of the lead...

Morgan Stanley has upgraded Bristol-Myers Squibb (NYSE: BMY) from Equal-weight to Overweight and has raised the price target from $28 to $34.

J.P. Morgan is out with its report today on Bristol-Myers Squibb (NYSE: BMY), maintaining Neutral. In a note to clients, J.P. Morgan writes, "Bristol presented first-line Yervoy data in the Plenary Session at ASCO yesterday. While the results gave us little reason to further increase our Yervoy...

Jefferies & Company has downgraded Bristol-Myers Squibb (NYSE: BMY) from Buy to Hold and maintains its $28.50.

Deutsche Bank has released an update on Bristol-Myers Squibb (NYSE: BMY) following the FDA Approval of Yervoy. According to Deutsche Bank, "FDA approval for Yervoy was expected, including severe labeling for potential irAEs, REMS for HC professionals and a patient medication guide. However,...

Goldman Sachs is out with its report on Bristol-Myers Squibb (NYSE: BMY), raising its price target from $30 to $32. In a note to clients, Goldman Sachs writes, "We raise our 12-month price target to $32 (from $30) based on 15X our revised 2013E EPS of $2.07. BMY is becoming more biotech than...

Goldman Sachs expects an on time FDA approval for Bristol-Myers Squibb Company (NYSE: BMY) ipi (renamed Yervoy) on its March 26 PDUFA for advanced melanoma in patient who have had prior therapy with REMS (second line) due to compelling data from study 020 and unmet medical need. “There is a chance...

Goldman Sachs is out with its report today on Bristol-Myers Squibb (NYSE: BMY), maintaining Buy. In a note to clients, Goldman Sachs writes, "After the market close today, Bristol Myers announced that the long-awaited 024 Phase III trial which studied ipilimumab in first-line metastatic melanoma...

In its look at Bristol-Myers Squibb (NYSE: BMY) product trends for the week ending 2-11-11, Citi reports the following. “Onglyza: ~$270M Annual Run Rate Implied by 4-Wk Avg TRx's vs. Our 2011E US Sales of $190M,” Citi writes. “Onglyza posted weekly NRx/TRx of 12,469 (+5%)/30,443 (+1%), with DPP-IV...

Jefferies is commenting on Bristol-Myers Squibb (NYSE: BMY) financials. “We expect positive newsflow on ipilimumab during Q1'11, specifically with regard to 1st-line melanoma data and the approval of a 2nd-line indication,” Jefferies writes. “Further visibility on apixaban in SPAF (Q2'11) and the...

Morgan Stanley is lowering its 2011e EPS on Bristol-Myers Squibb (NYSE: BMY) from $2.30 to $2.23. “Our new EPS estimate is $0.02 below consensus,” Morgan Stanley writes. “We tweaked our model to reflect second-line ipilimumab launch in 3Q:11. Our 2011e probability-adjusted ipilimumab sales changed...

Citigroup has published a research report on Bristol-Myers Squibb (NYSE: BMY) after the company reported solid 18 month Sprycel data at the American Society of Hematology meeting in Orlando, Florida. In the report, Citigroup writes "Sprycel efficacy in the 18-month 1st -line chronic myelogenous...